AxoGen is a biotech company developing treatment options for the reconstruction and repair of peripheral nerve injuries. It is passionate about restoring nerve function and quality of life to patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body.
AxoGen's portfolio of products includes Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves, AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a soft tissue covering to reduce inflammation and scar tissue formation. 

Type
Public
HQ
Alachua, US
Founded
2002
Size (employees)
114 (est)+41%
AxoGen was founded in 2002 and is headquartered in Alachua, US

Key People at AxoGen

Karen Zaderej

Karen Zaderej

CEO
Gregory G. Freitag

Gregory G. Freitag

General Counsel, SVP Business Development, Director

AxoGen Office Locations

AxoGen has an office in Alachua
Alachua, US (HQ)
13631 Progress Blvd

AxoGen Data and Metrics

AxoGen Financial Metrics

AxoGen's revenue was reported to be $12.2 m in Q1, 2017
USD

Revenue (Q1, 2017)

12.2 m

Gross profit (Q1, 2017)

10.3 m

Gross profit margin (Q1, 2017), %

84%

Net income (Q1, 2017)

(3.8 m)

EBIT (Q1, 2017)

(3.2 m)

Market capitalization (18-Aug-2017)

515.1 m

Cash (31-Mar-2017)

25.9 m
AxoGen's current market capitalization is $515.1 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

10.9 m16.8 m27.3 m41.1 m

Revenue growth, %

54%63%50%

Cost of goods sold

2.4 m3.4 m4.8 m6.5 m

Gross profit

8.5 m13.4 m22.5 m34.6 m

Gross profit Margin, %

78%80%82%84%

Sales and marketing expense

28.4 m

R&D expense

4.2 m

General and administrative expense

10.1 m

Operating expense total

42.8 m

EBIT

(9.6 m)(9.8 m)(9.3 m)(8.1 m)

EBIT margin, %

(88%)(58%)(34%)(20%)

Interest expense

4.8 m6.8 m4 m5.4 m

Pre tax profit

(14.6 m)

Net Income

(14.6 m)(17.7 m)(13.4 m)(14.4 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

4.2 m4.7 m5 m6.4 m8.2 m8.1 m10.4 m11.2 m12.2 m

Cost of goods sold

887.8 k896.2 k982.9 k1 m1.4 m1.4 m1.5 m1.7 m1.9 m

Gross profit

3.3 m3.8 m4 m5.4 m6.7 m6.7 m8.8 m9.5 m10.3 m

Gross profit Margin, %

79%81%80%84%83%83%85%85%84%

Sales and marketing expense

3.4 m3.3 m3.9 m4.8 m5.5 m6.2 m6.8 m7.1 m8.6 m

R&D expense

555.8 k681.2 k736.4 k936 k978.3 k936.8 k1.1 m1.4 m

General and administrative expense

1.7 m1.6 m1.9 m2 m2.2 m2.1 m2.7 m2.5 m3.5 m

Operating expense total

5.6 m5.6 m5.8 m7.5 m8.7 m9.3 m10.5 m10.7 m13.5 m

EBIT

(2.3 m)(1.8 m)(2.5 m)(2.2 m)(1.9 m)(2.6 m)(1.6 m)(1.2 m)(3.2 m)

EBIT margin, %

(55%)(39%)(51%)(34%)(24%)(32%)(15%)(11%)(26%)

Interest expense

1.4 m1.4 m994.7 k1 m1 m1 m1.2 m1.1 m507.5 k

Net Income

(3.7 m)(3.2 m)(3.6 m)(3.2 m)(3 m)(3.7 m)(2.8 m)(2.3 m)(3.8 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

20.1 m8.2 m25.9 m30 m

Accounts Receivable

1.2 b

Inventories

3.4 m3.2 m3.9 m5.5 m

Current Assets

25.7 m14.4 m35.1 m44 m

PP&E

381.7 k619 k970.9 k1.5 m

Total Assets

27.7 m16.4 m37.5 m46.4 m

Accounts Payable

2.1 m2.4 m3.7 m7 m

Current Liabilities

2.1 m2.4 m3.7 m11.1 m

Total Liabilities

31.4 m

Additional Paid-in Capital

72.4 m78.7 m111.4 m132.5 m

Retained Earnings

(72.4 m)(90.1 m)(103.5 m)(117.9 m)

Total Equity

136.6 k(11.2 m)8.2 m14.9 m

Financial Leverage

202.6 x-1.5 x4.6 x3.1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

14.2 m11.8 m19.3 m15.6 m29.9 m20.9 m18.3 m16 m25.9 m

Inventories

3.4 m3.3 m3.3 m3.5 m3.7 m4.5 m4.8 m5 m5.9 m

Current Assets

20.3 m18 m26 m23.2 m38.6 m31.5 m29.7 m28.7 m40.9 m

PP&E

597.3 k613.2 k583.4 k663.9 k830.1 k1.3 m1.3 m1.3 m1.5 m

Total Assets

22.4 m20.1 m28.1 m25.4 m40.9 m33.5 m31.8 m30.8 m43.3 m

Accounts Payable

2.2 m2 m3.4 m3.4 m4.1 m3.8 m3.9 m4.6 m6.7 m

Current Liabilities

2.3 m2 m3.4 m3.4 m4.1 m3.8 m3.9 m4.6 m10.7 m

Additional Paid-in Capital

73 m73.3 m92.8 m93.1 m110.7 m111.7 m112.4 m113.1 m133.4 m

Retained Earnings

(80.4 m)(83.6 m)(93.7 m)(96.9 m)(99.9 m)(107.1 m)(110 m)(112.3 m)(121.6 m)

Total Equity

(7.2 m)(10.2 m)(680.5 k)(3.5 m)11.2 m4.8 m2.8 m1.1 m12.1 m

Financial Leverage

-3.1 x-2 x-41.3 x-7.2 x3.7 x6.9 x11.4 x27.9 x3.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(14.6 m)(17.7 m)(13.4 m)(14.4 m)

Depreciation and Amortization

138.3 k198.9 k249 k

Accounts Receivable

(902.2 k)(1 m)(2 m)

Inventories

(247.3 k)184.8 k(720.3 k)5.5 m

Accounts Payable

430.6 k498.3 k1.1 m7 m

Cash From Operating Activities

(10.4 m)(10.5 m)(13.1 m)

Purchases of PP&E

(178.8 k)(542 k)(408.8 k)

Cash From Investing Activities

(244 k)(594 k)(555.5 k)

Long-term Borrowings

(1.8 m)(1.8 m)

Cash From Financing Activities

16.9 m31.3 m

Interest Paid

1 m3.9 m3.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(3.7 m)(3.2 m)(3.6 m)(3.2 m)(3 m)(3.7 m)(2.8 m)(2.3 m)(3.8 m)

Inventories

3.4 m3.3 m3.3 m3.5 m3.7 m4.5 m4.8 m5 m5.9 m

Accounts Payable

2.2 m2 m3.4 m3.4 m4.1 m3.8 m3.9 m4.6 m6.7 m
Y, 2017

Financial Leverage

3.6 x

AxoGen Market Value History

Traffic Overview of AxoGen

AxoGen Online and Social Media Presence

AxoGen Company Life and Culture

You may also be interested in